Green Acid Mediated Synthesis of Imidazo[1,2-a]Pyrimidine-Thiazole/1,3,4-Thiadiazole Hybrids: Design, Characterization and In-Vitro Biological Evaluation.
4 affiliations
- 1Organic and Medicinal Chemistry Laboratory, Department of Chemistry, National Institute of Technology Karnataka, Mangalore, Karnataka, India.
- 2School of Sciences, Woxsen University, Hyderabad, India.
- 3Nitte (Deemed to Be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutical Chemistry, Mangalore, Karnataka, India.
- 4Department of Chemistry, Central University of Karnataka, Kalaburagi, Karnataka, India.
Abstract
This work reports the design and development of two series of imine-linked imidazo[1,2-a]pyrimidine-thiazole/1,3,4-thiadiazole derivatives using a molecular hybridization approach as anti-tubercular agents. A total of thirty-seven new hybrid compounds (B1-B37) were synthesized and characterized. One final molecule, B20, was structurally confirmed by single-crystal x-ray diffraction analysis. All the final compounds (B1-B37) were tested for activity against the Mycobacterium tuberculosis H37Rv strain. Compounds B5, B26, and B30 exhibited significant inhibitory effects, with MICs of 12.5, 12.5, and 6.25 µg/mL, respectively. All novel final compounds also displayed effective antibacterial action against four bacterial strains S. aureus, E. coli, B. subtilis, and P. aeruginosa. Toxicity tests on mouse fibroblast (L929) cell lines revealed that the highly active anti-TB compounds (B5, B26, and B30) were nontoxic. Furthermore, the outcomes of the in silico ADME evaluation, DFT analysis, molecular docking studies (targeting CYP121 and InhA), and dynamic simulation demonstrated the potent compounds' great potential as prospective scaffolds for the development of novel antitubercular drugs.
Related
- Design, synthesis, and biological evaluation of novel 4,5-diaryl-1,2,3-thiadiazole derivatives: anticancer activity and molecular docking studies
- Antimony(III) and Bismuth(III) Halide Complexes Containing Thiazole-and Thiadiazole-Based Mercapto Ligands: Synthesis, Structural Characterization, and Biological Activity
- Pyridine-3-Carboxamide–1,3,4-Thiadiazole Hybrids as Antimicrobial Agents: Synthesis, Biological Evaluation, In Vivo Toxicity, and Computational Studies
- Synthesis, characterization and biological evaluation of newly designed silver(I)-N-heterocyclic carbene (NHC) complexes
- Phytogenic Synthesis of Platinum Nanoparticles: Characterization and In Vitro Biological Evaluation of Antioxidant, Antimicrobial, and Anticancer Activities.
BibTeX
@article{dinesha2026green,
title = {{Green Acid Mediated Synthesis of Imidazo[1,2-a]Pyrimidine-Thiazole/1,3,4-Thiadiazole Hybrids: Design, Characterization and In-Vitro Biological Evaluation.}},
author = {Dinesha P and Shivakumar Naik and Udayakumar D and Maithilee S Dhekale and Sampat Parayya Vibhutimath and Rajkumar Reddy Rajula and Revanasiddappa B C and Nanditha Bhat and Naveena S Veeranagaiah},
journal = {Chemistry \& biodiversity},
year = {2026},
month = oct,
doi = {10.1002/cbdv.71857},
url = {https://europepmc.org/article/MED/42904789},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Green Acid Mediated Synthesis of Imidazo[1,2-a]Pyrimidine-Thiazole/1,3,4-Thiadiazole Hybrids: Design, Characterization and In-Vitro Biological Evaluation.
AU - Dinesha P
AU - Shivakumar Naik
AU - Udayakumar D
AU - Maithilee S Dhekale
AU - Sampat Parayya Vibhutimath
AU - Rajkumar Reddy Rajula
AU - Revanasiddappa B C
AU - Nanditha Bhat
AU - Naveena S Veeranagaiah
PY - 2026
DA - 2026/10/01
JO - Chemistry & biodiversity
DO - 10.1002/cbdv.71857
UR - https://europepmc.org/article/MED/42904789
AB - This work reports the design and development of two series of imine-linked imidazo[1,2-a]pyrimidine-thiazole/1,3,4-thiadiazole derivatives using a molecular hybridization approach as anti-tubercular agents. A total of thirty-seven new hybrid compounds (B1-B37) were synthesized and characterized. One final molecule, B20, was structurally confirmed by single-crystal x-ray diffraction analysis. All the final compounds (B1-B37) were tested for activity against the Mycobacterium tuberculosis H37Rv strain. Compounds B5, B26, and B30 exhibited significant inhibitory effects, with MICs of 12.5, 12.5, and 6.25 µg/mL, respectively. All novel final compounds also displayed effective antibacterial action against four bacterial strains S. aureus, E. coli, B. subtilis, and P. aeruginosa. Toxicity tests on mouse fibroblast (L929) cell lines revealed that the highly active anti-TB compounds (B5, B26, and B30) were nontoxic. Furthermore, the outcomes of the in silico ADME evaluation, DFT analysis, molecular docking studies (targeting CYP121 and InhA), and dynamic simulation demonstrated the potent compounds' great potential as prospective scaffolds for the development of novel antitubercular drugs.
SN - 1612-1872
SN - 1612-1880
ER -